NOT FOR DISTRIBUTION
Header cover image

Market Cap

CN¥17.7b

Last Updated

2021/04/11 09:02 UTC

Data Sources

Company Financials +

Executive Summary

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. More Details


Snowflake Analysis

Very undervalued with excellent balance sheet.

Share Price & News

How has Hubei Jumpcan Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 600566 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 600566's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-1.3%

600566

-0.1%

CN Pharmaceuticals

-1.1%

CN Market


1 Year Return

-8.4%

600566

15.8%

CN Pharmaceuticals

28.4%

CN Market

Return vs Industry: 600566 underperformed the CN Pharmaceuticals industry which returned 14.4% over the past year.

Return vs Market: 600566 underperformed the CN Market which returned 27.4% over the past year.


Shareholder returns

600566IndustryMarket
7 Day-1.3%-0.1%-1.1%
30 Day-1.4%3.9%1.0%
90 Day-1.2%-5.4%-5.8%
1 Year-3.2%-8.4%16.9%15.8%30.4%28.4%
3 Year-54.0%-58.8%25.2%20.7%25.9%19.9%
5 Year-6.0%-20.0%41.6%34.1%23.6%15.5%

Long-Term Price Volatility Vs. Market

How volatile is Hubei Jumpcan Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hubei Jumpcan Pharmaceutical undervalued compared to its fair value and its price relative to the market?

23.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 600566 (CN¥19.94) is trading below our estimate of fair value (CN¥26.07)

Significantly Below Fair Value: 600566 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 600566 is good value based on its PE Ratio (12.7x) compared to the CN Pharmaceuticals industry average (30.9x).

PE vs Market: 600566 is good value based on its PE Ratio (12.7x) compared to the CN market (34.5x).


Price to Earnings Growth Ratio

PEG Ratio: 600566 is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: 600566 is good value based on its PB Ratio (2.4x) compared to the CN Pharmaceuticals industry average (2.8x).


Future Growth

How is Hubei Jumpcan Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

15.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600566's forecast earnings growth (15.2% per year) is above the savings rate (3.3%).

Earnings vs Market: 600566's earnings (15.2% per year) are forecast to grow slower than the CN market (23.5% per year).

High Growth Earnings: 600566's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600566's revenue (12.8% per year) is forecast to grow slower than the CN market (18% per year).

High Growth Revenue: 600566's revenue (12.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 600566's Return on Equity is forecast to be low in 3 years time (16.7%).


Past Performance

How has Hubei Jumpcan Pharmaceutical performed over the past 5 years?

16.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 600566 has high quality earnings.

Growing Profit Margin: 600566's current net profit margins (21.8%) are lower than last year (23.9%).


Past Earnings Growth Analysis

Earnings Trend: 600566's earnings have grown by 16.5% per year over the past 5 years.

Accelerating Growth: 600566's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600566 had negative earnings growth (-24.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.9%).


Return on Equity

High ROE: 600566's Return on Equity (17.2%) is considered low.


Financial Health

How is Hubei Jumpcan Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 600566's short term assets (CN¥6.1B) exceed its short term liabilities (CN¥1.8B).

Long Term Liabilities: 600566's short term assets (CN¥6.1B) exceed its long term liabilities (CN¥792.7M).


Debt to Equity History and Analysis

Debt Level: 600566's debt to equity ratio (8.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 600566's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 600566's debt is well covered by operating cash flow (298.5%).

Interest Coverage: 600566 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Hubei Jumpcan Pharmaceutical current dividend yield, its reliability and sustainability?

6.17%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 600566's dividend (6.17%) is higher than the bottom 25% of dividend payers in the CN market (0.42%).

High Dividend: 600566's dividend (6.17%) is in the top 25% of dividend payers in the CN market (1.79%)


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 600566 has been paying a dividend for less than 10 years.

Growing Dividend: 600566's dividend payments have increased, but the company has only paid a dividend for 6 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (78.6%), 600566's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average board tenure


CEO

Fei Cao (37 yo)

1.33yrs

Tenure

Mr. Fei Cao serves as General Manager of Jiangsu Jumpcan Holding Group Co., Ltd. Mr. Cao serves as Chairman of Shaanxi Dongke Pharmaceutical Co., Ltd. Mr. Cao serves as Vice Chairman of Hubei Jumpcan Pharm...


Board Members

Experienced Board: 600566's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.


Top Shareholders

Company Information

Hubei Jumpcan Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hubei Jumpcan Pharmaceutical Co., Ltd.
  • Ticker: 600566
  • Exchange: SHSE
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥17.712b
  • Shares outstanding: 888.26m
  • Website: https://www.jumpcan.com

Number of Employees


Location

  • Hubei Jumpcan Pharmaceutical Co., Ltd.
  • Baota Bay
  • West Daqing Road
  • Taixing
  • Jiangsu Province
  • 225441
  • China

Listings


Biography

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional med...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 09:02
End of Day Share Price2021/04/09 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.